<DOC>
	<DOCNO>NCT03071068</DOCNO>
	<brief_summary>This study conduct evaluate safety THR-317 administer intravitreally assess compound 's efficacy improve best-corrected visual acuity ( BCVA ) reduce central subfield thickness ( CST ) subject centre-involved diabetic macular oedema ( DME ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy THR-317 Treatment Diabetic Macular Oedema ( DME )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Male female age 18 year old Type 1 type 2 diabetes Centreinvolved DME CST ≥ 340µm Spectralis SDOCT ≥ 320µm nonSpectralis SD OCT , study eye Reduced vision primarily due DME , BCVA 72 23 ETDRS letter read 4 meter ( 20/40 20/320 Snellen equivalent ) study eye Antivascular endothelial growth factor ( antiVEGF ) treatment naïve study eye poor response prior antiVEGF treatment study eye Nonproliferative diabetic retinopathy , stable proliferative diabetic retinopathy without neovacularisation disc Written inform consent obtain subject prior screening procedure Exclusion criterion : Concurrent disease study eye , DME , could compromise BCVA , require medical surgical intervention study period could confound interpretation result Previous treatment / procedure study eye follow , plan use THR317 treatment period 30 day last injection : panretinal focal / grid laser photocoagulation [ 3 month ] , antiVEGF treatment [ time antiVEGF naïve subject ; 4 week subject poor response antiVEGF treatment ] , intraocular periocular corticosteroid [ 4 month ] , steroid implant [ time ] , intraocular surgery [ 3 month ] , vitrectomy [ time ] Any active ocular / intraocular infection inflammation either eye Aphakic study eye Untreated diabetes Glycated haemoglobin A ( HbA1c ) &gt; 12 % Uncontrolled hypertension opinion Investigator Pregnant lactate female female childbearing potential utilising adequate form contraception male reproductive potential utilising contraception suggest lens / zonular instability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>